A phase II 'window' study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia

Steven D. Gore, Eric K. Rowinsky, Carole B. Miller, Constance Griffin, Tian Ling Chen, Michael Borowitz, Ross C. Donehower, Kathleen L. Burks, Deborah K. Armstrong, Philip J. Burke, Michael R. Grever, Scott H Kaufmann

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

To further evaluate the activity of topotecan (TPT) in acute leukemia, TPT was administered (2.1 mg/m2/day for 5 days by continuous i.v. infusion) to adult patients with previously untreated acute lymphoblastic leukemia (ALL) with high-risk features (13 patients) or relapsed ALL (1 patient). Patients achieving a partial response or significant hematological improvement received a second course. All patients subsequently received standard treatment for ALL. Because complete response was achieved in only 1 of 14 patients, the study was terminated prematurely. An additional patient achieved minimal response, and a third patient normalized her hemogram despite ongoing leukemia in the marrow. Overall, six patients had significant hematological improvement (normalization of platelet and/or absolute neutrophil count). Two patients expired due to infections during induction chemotherapy. The primary nonhematological toxicities were mucositis and diarrhea. Exposure to TPT did not appear to influence the response to subsequent standard chemotherapy. The mean steady-state TPT plasma concentration, 16.1 ± 1 nM, overlapped the range of LD90 values of primary human leukemia specimens. Cellular topo I content varied over a 3-fold range, encompassing levels found previously in relapsed patients. No relationship was found between topo I expression and markers of cellular proliferation or response to therapy. In contrast, low expression of the apoptosis inhibitor Bcl-2 was associated with response to TPT therapy. TPT has significant, albeit modest, single-agent activity against high-risk adult ALL. This study demonstrates the feasibility of evaluating promising new therapeutic agents in untreated patients with acute leukemia at high risk for failure with conventional therapy.

Original languageEnglish (US)
Pages (from-to)2677-2689
Number of pages13
JournalClinical Cancer Research
Volume4
Issue number11
StatePublished - Nov 1998

Fingerprint

Topotecan
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia
Therapeutics
Mucositis
Induction Chemotherapy
Feasibility Studies
Diarrhea

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gore, S. D., Rowinsky, E. K., Miller, C. B., Griffin, C., Chen, T. L., Borowitz, M., ... Kaufmann, S. H. (1998). A phase II 'window' study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. Clinical Cancer Research, 4(11), 2677-2689.

A phase II 'window' study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. / Gore, Steven D.; Rowinsky, Eric K.; Miller, Carole B.; Griffin, Constance; Chen, Tian Ling; Borowitz, Michael; Donehower, Ross C.; Burks, Kathleen L.; Armstrong, Deborah K.; Burke, Philip J.; Grever, Michael R.; Kaufmann, Scott H.

In: Clinical Cancer Research, Vol. 4, No. 11, 11.1998, p. 2677-2689.

Research output: Contribution to journalArticle

Gore, SD, Rowinsky, EK, Miller, CB, Griffin, C, Chen, TL, Borowitz, M, Donehower, RC, Burks, KL, Armstrong, DK, Burke, PJ, Grever, MR & Kaufmann, SH 1998, 'A phase II 'window' study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia', Clinical Cancer Research, vol. 4, no. 11, pp. 2677-2689.
Gore SD, Rowinsky EK, Miller CB, Griffin C, Chen TL, Borowitz M et al. A phase II 'window' study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. Clinical Cancer Research. 1998 Nov;4(11):2677-2689.
Gore, Steven D. ; Rowinsky, Eric K. ; Miller, Carole B. ; Griffin, Constance ; Chen, Tian Ling ; Borowitz, Michael ; Donehower, Ross C. ; Burks, Kathleen L. ; Armstrong, Deborah K. ; Burke, Philip J. ; Grever, Michael R. ; Kaufmann, Scott H. / A phase II 'window' study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. In: Clinical Cancer Research. 1998 ; Vol. 4, No. 11. pp. 2677-2689.
@article{b1dfa4f643a3413e968b672c5ec0e58d,
title = "A phase II 'window' study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia",
abstract = "To further evaluate the activity of topotecan (TPT) in acute leukemia, TPT was administered (2.1 mg/m2/day for 5 days by continuous i.v. infusion) to adult patients with previously untreated acute lymphoblastic leukemia (ALL) with high-risk features (13 patients) or relapsed ALL (1 patient). Patients achieving a partial response or significant hematological improvement received a second course. All patients subsequently received standard treatment for ALL. Because complete response was achieved in only 1 of 14 patients, the study was terminated prematurely. An additional patient achieved minimal response, and a third patient normalized her hemogram despite ongoing leukemia in the marrow. Overall, six patients had significant hematological improvement (normalization of platelet and/or absolute neutrophil count). Two patients expired due to infections during induction chemotherapy. The primary nonhematological toxicities were mucositis and diarrhea. Exposure to TPT did not appear to influence the response to subsequent standard chemotherapy. The mean steady-state TPT plasma concentration, 16.1 ± 1 nM, overlapped the range of LD90 values of primary human leukemia specimens. Cellular topo I content varied over a 3-fold range, encompassing levels found previously in relapsed patients. No relationship was found between topo I expression and markers of cellular proliferation or response to therapy. In contrast, low expression of the apoptosis inhibitor Bcl-2 was associated with response to TPT therapy. TPT has significant, albeit modest, single-agent activity against high-risk adult ALL. This study demonstrates the feasibility of evaluating promising new therapeutic agents in untreated patients with acute leukemia at high risk for failure with conventional therapy.",
author = "Gore, {Steven D.} and Rowinsky, {Eric K.} and Miller, {Carole B.} and Constance Griffin and Chen, {Tian Ling} and Michael Borowitz and Donehower, {Ross C.} and Burks, {Kathleen L.} and Armstrong, {Deborah K.} and Burke, {Philip J.} and Grever, {Michael R.} and Kaufmann, {Scott H}",
year = "1998",
month = "11",
language = "English (US)",
volume = "4",
pages = "2677--2689",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - A phase II 'window' study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia

AU - Gore, Steven D.

AU - Rowinsky, Eric K.

AU - Miller, Carole B.

AU - Griffin, Constance

AU - Chen, Tian Ling

AU - Borowitz, Michael

AU - Donehower, Ross C.

AU - Burks, Kathleen L.

AU - Armstrong, Deborah K.

AU - Burke, Philip J.

AU - Grever, Michael R.

AU - Kaufmann, Scott H

PY - 1998/11

Y1 - 1998/11

N2 - To further evaluate the activity of topotecan (TPT) in acute leukemia, TPT was administered (2.1 mg/m2/day for 5 days by continuous i.v. infusion) to adult patients with previously untreated acute lymphoblastic leukemia (ALL) with high-risk features (13 patients) or relapsed ALL (1 patient). Patients achieving a partial response or significant hematological improvement received a second course. All patients subsequently received standard treatment for ALL. Because complete response was achieved in only 1 of 14 patients, the study was terminated prematurely. An additional patient achieved minimal response, and a third patient normalized her hemogram despite ongoing leukemia in the marrow. Overall, six patients had significant hematological improvement (normalization of platelet and/or absolute neutrophil count). Two patients expired due to infections during induction chemotherapy. The primary nonhematological toxicities were mucositis and diarrhea. Exposure to TPT did not appear to influence the response to subsequent standard chemotherapy. The mean steady-state TPT plasma concentration, 16.1 ± 1 nM, overlapped the range of LD90 values of primary human leukemia specimens. Cellular topo I content varied over a 3-fold range, encompassing levels found previously in relapsed patients. No relationship was found between topo I expression and markers of cellular proliferation or response to therapy. In contrast, low expression of the apoptosis inhibitor Bcl-2 was associated with response to TPT therapy. TPT has significant, albeit modest, single-agent activity against high-risk adult ALL. This study demonstrates the feasibility of evaluating promising new therapeutic agents in untreated patients with acute leukemia at high risk for failure with conventional therapy.

AB - To further evaluate the activity of topotecan (TPT) in acute leukemia, TPT was administered (2.1 mg/m2/day for 5 days by continuous i.v. infusion) to adult patients with previously untreated acute lymphoblastic leukemia (ALL) with high-risk features (13 patients) or relapsed ALL (1 patient). Patients achieving a partial response or significant hematological improvement received a second course. All patients subsequently received standard treatment for ALL. Because complete response was achieved in only 1 of 14 patients, the study was terminated prematurely. An additional patient achieved minimal response, and a third patient normalized her hemogram despite ongoing leukemia in the marrow. Overall, six patients had significant hematological improvement (normalization of platelet and/or absolute neutrophil count). Two patients expired due to infections during induction chemotherapy. The primary nonhematological toxicities were mucositis and diarrhea. Exposure to TPT did not appear to influence the response to subsequent standard chemotherapy. The mean steady-state TPT plasma concentration, 16.1 ± 1 nM, overlapped the range of LD90 values of primary human leukemia specimens. Cellular topo I content varied over a 3-fold range, encompassing levels found previously in relapsed patients. No relationship was found between topo I expression and markers of cellular proliferation or response to therapy. In contrast, low expression of the apoptosis inhibitor Bcl-2 was associated with response to TPT therapy. TPT has significant, albeit modest, single-agent activity against high-risk adult ALL. This study demonstrates the feasibility of evaluating promising new therapeutic agents in untreated patients with acute leukemia at high risk for failure with conventional therapy.

UR - http://www.scopus.com/inward/record.url?scp=0031784683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031784683&partnerID=8YFLogxK

M3 - Article

C2 - 9829730

AN - SCOPUS:0031784683

VL - 4

SP - 2677

EP - 2689

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -